LH — Labcorp Holdings Inc.

Market sentiment is clearly bullish: Q2 2026 adjusted EPS of $4.99 beat the $4.78 consensus, revenue grew 5.8% YoY to $3.73B, management raised full-year 2026 EPS guidance to $18.10-$18.55, and banks like JPMorgan and UBS lifted targets to $360-$361. The Roche Alzheimer's blood test partnership adds a high-profile growth narrative, and the stock has outperformed the S&P 500 year-to-date.

The 3-year trend is a genuine inflection from a weak 2023 to steady mid-single-digit growth and meaningful margin expansion by 2026. Q2 2026 revenue rose 5.8% YoY to $3.731B, operating margin improved to 12.1% from 11.2% a year earlier, and diluted EPS jumped to $3.64 from $2.84. Q1 2026 and Q3 2025 similarly showed solid growth, so this is not a one-off blip. Free cash flow is lumpier - Q2 2026 FCF was $313.9M vs $542.7M in Q2 2025 - but trailing FCF is roughly stable near $1.2B, and reported earnings quality remains reasonable with a negative accruals ratio.

As of 2026-08-27, Labcorp is expensive versus its own history: trailing P/E is 27.7x vs the 5-year average of 24.5x, and price-to-sales is 1.92x vs the 5-year average of 1.63x. On FY2026 estimated EPS of $18.33, forward P/E is about 18.4x, which is not extreme, but the headline PEG of 0.83 relies on an aggressive long-term growth assumption that revenue growth (mid-single digits) does not support without continued margin expansion and buybacks.

At $336.54, the stock is pricing in the Q2 guidance raise and the Alzheimer's test optionality before those benefits fully show up in cash flow. It trades above the consensus target of $328.50 and the recent average of $334.20. If Labcorp hits the high end of guidance and the Alzheimer's rollout gains traction, upside toward $350-$360 is plausible; if Q3 disappoints or FCF growth fails to confirm EPS growth, the stock could revert toward 16-17x forward earnings, roughly $295-$312.

As of 2026-08-27, RSI stood at 71.97, which is overbought. Price is 3.86% above the 20-day SMA, 12.92% above the 50-day SMA, and 23.0% above the 200-day SMA. The trend is strongly bullish but extended; chasing here is poor timing. A pullback toward the 20-day or 50-day SMA would offer a much better entry than buying at current levels.

• Healthcare sector rotation: investors have favored defensive healthcare, supporting diagnostics names like Labcorp.
• Reimbursement pressure from public and private payors continues to threaten pricing and requires ongoing automation (LaunchPad) to protect margins.
• Labor and supply-chain cost inflation in lab networks remains a structural margin headwind.
• Stabilizing biopharma and central-labs markets are supporting Labcorp's Biopharma Laboratory Services backlog.
• Higher interest rates matter because Labcorp carries meaningful debt ($5.86B long-term) and only $142M cash, making free cash flow conversion important.

• Q3 2026 earnings in late October/early November 2026, where investors will look for confirmation of raised FY2026 EPS guidance of $18.10-$18.55.
• Broad rollout and commercial adoption of Roche's Elecsys pTau-217 Alzheimer's blood test in primary and specialty care.
• Continued momentum in high-margin specialty diagnostics (oncology, neurology, autoimmune) and integration of the $155M hospital outreach lab asset acquisition.

• Reimbursement cuts or slower volume growth in routine diagnostics could pressure the core business.
• The stock is overbought and extended: 23% above the 200-day SMA and above the average analyst target, leaving little margin of safety.
• Free cash flow is volatile and not yet growing in line with reported EPS; TTM FCF of ~$1.2B is thin relative to the $27.6B market cap, and the balance sheet carries high debt with low cash.
• Competition from Quest Diagnostics and other labs, plus execution risk in new Alzheimer's and oncology tests, could keep margin expansion below expectations.

Labcorp is a solid diagnostics franchise with improving margins and credible growth drivers, but as of 2026-08-27 it is not a good entry point. The stock is expensive versus its own history, technically overbought, and trading above the average analyst target, while the deterministic score flags weak backward-looking fundamentals. The risk/reward tilts bearish at $336.54; wait for a pullback toward the low-to-mid $300s or for FCF growth to catch up with EPS momentum.

Simplified 10-year DCF using normalized FCF of $1.35B growing at 8% annually, a 9.0% WACC, 2.5% terminal growth, and net debt of $5.72B over ~82M shares yields about $312 per share. This is below the current price and reflects the gap between reported EPS momentum and actual free cash flow generation.